A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 1995-11, Vol.72 (5), p.1256-1258
Hauptverfasser:	IAFFAIOLI, R. V, TORTORIELLO, A, ANTONELLI, B, VALLEFUOCO, V, MOSELLA, G, CAPONIGRO, F, FACCHINI, G, SANTANGELO, M, DE SENA, G, GESUE', G, BUCCI, L, SCARAMELLINO, G, ANASTASIO, E, FINIZIO, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Female Follow-Up Studies Granulocyte Colony-Stimulating Factor - therapeutic use Humans Leukopenia - chemically induced Medical sciences Neoplasm Metastasis Pharmacology. Drug treatments Phlebitis - chemically induced Remission Induction Salvage Therapy Treatment Outcome Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives Vinorelbine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
ISSN:	0007-0920 1532-1827
DOI:	10.1038/bjc.1995.496